Search Results
Aug 02, 2026, 10:01 ET New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
otherwise not have ready access to such therapies. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. Additional information can
More news about: Specialised Therapeutics
Jul 31, 2026, 07:00 ET Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy
development of RNA-based solutions, including siRNAs, where applicable, to target life-threatening, fast-progressing conditions such as those in the CNS. Committed to scientific excellence and patient-centered innovation, Ractigen strives to transform healthcare through the power of RNA therapeutics.
More news about: Ractigen Therapeutics
Jul 30, 2026, 21:01 ET Kaigene Enters into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in Japan
barrier. Through this platform, the company is developing multiple therapeutic candidates aimed at addressing the significant unmet clinical needs in CNS autoimmune diseases, an area that remains largely unexplored.For more information, please visit
More news about: Kaigene
Jul 30, 2026, 16:17 ET Cohen & Steers, Inc. Declares Quarterly Dividend
NEW YORK, July 30, 2026 /PRNewswire/ -- The Board of Directors of Cohen & Steers, Inc. (NYSE: CNS) declared a cash dividend for the third quarter of 2026 in the amount of $0.67 per share of common stock payable on August 20, 2026 to stockholders of
More news about: Cohen & Steers, Inc.
Jul 30, 2026, 08:00 ET TSC Alliance and Apertura Gene Therapy Complete Preclinical Pilot Study Evaluating AAV Gene Therapy Approach Designed for TSC1
manufacturing by contract development and manufacturing organizations. TfR1 CapX is a proprietary, second-generation capsid that demonstrates superior CNS delivery compared to Apertura's first-generation capsid, BI-hTFR1. Research on the first-generation BI-hTFR1 capsid was published in
More news about: TSC Alliance
Jul 29, 2026, 16:06 ET CPKC Announces Retirement of Board Chair Isabelle Courville; Vice-Chair Gordon Trafton Appointed Chair of the Board
Senior Vice-President Strategic Acquisitions and Integration and as Senior Vice-President, Southern Region at CN. Prior to that, Mr. Trafton worked as CN's Vice President, Operations Integration."On behalf of my fellow board members, I thank Isabelle for her outstanding leadership and invaluable
More news about: CPKC
Jul 29, 2026, 16:05 ET Cohen & Steers Closed-end Opportunity Fund, Inc. Issues Important Notice Regarding Change in Investment Policy and Investment Strategy
https://www.cohenandsteers.com/Symbols: (NYSE: CNS, FOF)
More news about: Cohen & Steers, Inc.
Jul 29, 2026, 13:14 ET GMP Biologics Market to Reach US$98.2 Bn by 2033 Accelerates with Biopharmaceutical Innovation - Persistence Market Research
Cancer Biomarkers Market by Product Type (Alpha-fetoprotein (AFP), Neuron-specific enolase (NSE), CD19, Others), Indication (Leukemia, Neuroblastoma, CNS Tumors, Others), End-use (Hospitals, Diagnostic Laboratories, Others), and Regional Analysis for 2026 – 2033About Persistence Market
More news about: Persistence Market Research Pvt. Ltd.
Jul 29, 2026, 09:57 ET Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms
Funding led by Guozhong Capital will accelerate Phase 2 development for saRNA candidate RAG-01 and CNS asset RAG-17, advance systemic saRNA program RAG-18 toward IND, and expand extrahepatic RNA delivery technologies.NANTONG, China, July
More news about: Ractigen Therapeutics
Jul 28, 2026, 17:47 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jul 28, 2026, 17:36 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jul 28, 2026, 17:20 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jul 28, 2026, 17:04 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jul 28, 2026, 16:55 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jul 28, 2026, 09:40 ET Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026
clinical-stage, pharmaceutical company with operations in Roswell, Ga., Dublin, Ireland, and Hamilton, Bermuda. Saol is focused on development activity in CNS disorders such as spasticity and pain management, and orphan diseases. Saol is committed to providing and advancing therapeutic options for patients
More news about: Saol Therapeutics
Jul 28, 2026, 08:12 ET Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)
-- Dasher Neuroscience Holdings Inc. (TPEx: 7829) ("Dasher Neuroscience"), an AI-driven biopharmaceutical company focused on central nervous system (CNS) drug discovery and development, today announced that it has successfully completed patient enrollment in its global, multi-center Phase 2 clinical trial
More news about: Dasher Neuroscience Holdings Inc.
Jul 28, 2026, 08:12 ET Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)
-- Dasher Neuroscience Holdings Inc. (TPEx: 7829) ("Dasher Neuroscience"), an AI-driven biopharmaceutical company focused on central nervous system (CNS) drug discovery and development, today announced that it has successfully completed patient enrollment in its global, multi-center Phase 2 clinical trial
More news about: Dasher Neuroscience Holdings Inc.
Jul 28, 2026, 08:00 ET Cipla Receives U.S. FDA Approval for Generic Advair Diskus®
Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms
More news about: Cipla Limited
Jul 28, 2026, 07:00 ET Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
(ODF) formulation. The data demonstrate ~150% higher systemic bioavailability and ~300% significant increase in CNS exposure than conventional oral administration. In addition to enhancing CNS drug delivery, Aramchol's proprietary ODF formulation directly addresses one of the most common clinical challenges
More news about: Galmed Pharmaceuticals Ltd.
Jul 28, 2026, 07:00 ET Michelle Ragusa-McBain Of Corero Network Security Recognized On The CRN Top 100 Executives List For 2026
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), leader in real-time DDoS protection and service availability today announced that
More news about: Corero Network Security
Jul 23, 2026, 21:30 ET Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
the most common primary malignant brain tumor and accounts for nearly 50 percent of all gliomas and approximately 25 percent of all primary brain and CNS malignant tumors. The incidence of GBM in Europe is currently above 25,000 new cases each year, rising to over 100,000 cases per year worldwide. The
More news about: Laminar Pharmaceuticals, S.A.
Jul 23, 2026, 21:30 ET Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
the most common primary malignant brain tumor and accounts for nearly 50 percent of all gliomas and approximately 25 percent of all primary brain and CNS malignant tumors. The incidence of GBM in Europe is currently above 25,000 new cases each year, rising to over 100,000 cases per year worldwide. The
More news about: Laminar Pharmaceuticals, S.A.
Jul 23, 2026, 20:02 ET Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth
The Company now has nearly 30 innovative product candidates spanning immunology, oncology, obesity and metabolic diseases, and central nervous system (CNS) disorders—therapeutic areas with significant unmet medical needs. Multiple programs have advanced into clinical development.For respiratory and
More news about: Harbour BioMed
Jul 23, 2026, 18:49 ET China Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct Offering
markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable
More news about: China Pharma Holdings, Inc.
Jul 23, 2026, 12:00 ET Apertura Gene Therapy Named to Consortium Receiving Funding from the Advanced Research Projects Agency for Health (ARPA-H) THRIVE Program to Develop Gene Therapies for Rare Childhood Diseases
—Consortium led by the Broad Institute's Center for Therapeutic Genetics to use Apertura's novel CNS-targeted AAV capsid, TfR1 CapX™, for base and prime gene editing programs—NEW YORK, July 23, 2026
More news about: Apertura Gene Therapy